Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram
Autore:
Brosen, K; Naranjo, CA;
Indirizzi:
Univ So Denmark, Inst Publ Hlth, DK-5000 Odense, Denmark Univ So Denmark Odense Denmark DK-5000 ubl Hlth, DK-5000 Odense, Denmark Univ Toronto, Dept Pharmacol, Sunnybrook & Womens Coll,Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto Toronto ON Canada ns Coll,Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto, Dept Psychiat & Med, Sunnybrook & Womens Coll,Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto Toronto ON Canada ns Coll,Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto, Psychopharmacol Res Program, Sunnybrook & Womens Coll,Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto Toronto ON Canada ns Coll,Hlth Sci Ctr, Toronto, ON, Canada
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
fascicolo: 4, volume: 11, anno: 2001,
pagine: 275 - 283
SICI:
0924-977X(200108)11:4<275:ROPAPI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN LIVER-MICROSOMES; SEROTONIN REUPTAKE INHIBITORS; DEBRISOQUINE OXIDATION POLYMORPHISM; INTESTINAL P-GLYCOPROTEIN; DEPRESSIVE PATIENTS; HEALTHY-SUBJECTS; PLASMA-LEVELS; CLINICAL CONSEQUENCES; CONCOMITANT TREATMENT; ORAL BIOAVAILABILITY;
Keywords:
citalopram; SSRI; interaction; CYP;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
77
Recensione:
Indirizzi per estratti:
Indirizzo: Brosen, K Univ So Denmark, Inst Publ Hlth, Winslowparken 19, DK-5000 Odense, Denmark Univ So Denmark Winslowparken 19 Odense Denmark DK-5000 Denmark
Citazione:
K. Brosen e C.A. Naranjo, "Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram", EUR NEUROPS, 11(4), 2001, pp. 275-283

Abstract

Citalopram is a selective serotonin reuptake inhibitor that is N-demethylated to N-desmethylcitalopram partially by CYP2C19 and partially by CYP3A4 and N-desmethylcitalopram is further N-demethylated by CYP2D6 to the likewise inactive metabolite di-desmethyleitalopram. The two metabolites are not active. The fact that citalopram is metabolised by more than one CYP means that inhibition of its biotransformation by other drugs is less likely. Besides citalopram has a wide margin of safety, so even if there was a considerable change in serum concentration then this would most likely not be of clinical importance. In vitro citalopram does not inhibit CYP or does so onlyvery moderately. A number of studies in healthy subjects and patients haveconfirmed, that this also holds true in vivo. Thus no change in pharmacokinetics or only very small changes were observed when citalopram was given with CYP1A2 substrates (clozapine and therophylline), CYP2C9 (warfarin), CYP2C19 (imipramine and mephenytoin), CYP2D6 (sparteine, imipramine and amitriptyline) and CYP3A4 (carbamazepine and triazolam). At the pharmacodynamic level there have been a few documented cases of serotonin syndrome with citalopram and moclobemide and buspirone. It is concluded that citalopram is neither the source nor the cause of clinically important drug-drug interactions, (C) 2001 Elsevier Science BY All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:02:26